National study , a randomized, controlled , open-label , parallel-group study to compare the efficacy and safety of two different approaches with titration algorithm ( run by the medical vs managed by the patient ) for a new therapy with insulin glargine U300 in patients with diabetes type 2 [Studio nazionale, randomizzato, controllato, in aperto, a gruppi paralleli per confrontare l'efficacia e la sicurezza di due diversi approcci con algoritmo di titolazione (gestito dal medico vs gestito dal paziente) per una nuova terapia con insulina glargine U300 in pazienti con diabete di tipo 2]

Trial Profile

National study , a randomized, controlled , open-label , parallel-group study to compare the efficacy and safety of two different approaches with titration algorithm ( run by the medical vs managed by the patient ) for a new therapy with insulin glargine U300 in patients with diabetes type 2 [Studio nazionale, randomizzato, controllato, in aperto, a gruppi paralleli per confrontare l'efficacia e la sicurezza di due diversi approcci con algoritmo di titolazione (gestito dal medico vs gestito dal paziente) per una nuova terapia con insulina glargine U300 in pazienti con diabete di tipo 2]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top